NCT00668837View on ClinicalTrials.gov

A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305.

PHASE3CompletedINTERVENTIONAL

Enrollment

407

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

June 30, 2006

Conditions

Schizophrenia

Interventions

DRUG

Paliperidone

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00668837 - A 52 Week Open-label Extension Trial Following the Double-blind Efficacy and Safety Study R076477-SCH-305. | Biotech Hunter | Biotech Hunter